Overexpression of βIII-tubulin and survivin associated with drug resistance to docetaxel-based chemotherapy in advanced gastric cancer

Journal of B.U.ON.

Volumn 17, Issue 2, 2012, Pages 284-290

  Zheng, Wei E ^a   Chen, Hua ^a   Yuan, Shao Fei ^a   Wu, Li Li ^a   Zhang, Wu ^a   Sun, Hong Yu ^a   Chen, Wen Jun ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

III tubulin; Docetaxel; Gastric cancer; Survivin

Indexed keywords

BETA III TUBULIN; BETA TUBULIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; SURVIVIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; BONE MARROW SUPPRESSION; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FEMALE; GASTROINTESTINAL SYMPTOM; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PROTEIN FUNCTION; RETROSPECTIVE STUDY; STOMACH CANCER; STOMACH MUCOSA LESION; SURVIVAL RATE; TREATMENT RESPONSE;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PAPILLARY; CARCINOMA, SIGNET RING CELL; CASE-CONTROL STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INHIBITOR OF APOPTOSIS PROTEINS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS; TUBULIN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84863628234     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA: Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
2. Pieros M, Hernández G, Bray F. Increasing mortality rates of common malignancies in Colombia. Cancer 2004; 101: 2285-2292. (Pubitemid 39458685)
3. Stewart BW, Kleihues P. World Cancer Report, IARC Press, 2003.
4. Bodys H, Marek T, Wanczura P, Matusik P, Nowak A. Even young patients with no alarm symptoms should undergo endoscopy for earlier diagnosis of gastric cancer. Endoscopy 2003; 35: 61-67. (Pubitemid 36131252)
5. Talley NJ. How to manage the difficult-to-treat dyspeptic patient. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 35-42. (Pubitemid 46055958)
6. Kollmannsberger C, Quietzsch D, Haag C et al. A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 2000; 83: 458-462. (Pubitemid 30487857)
7. Ridwelski K, Gebauer T, Fahlke J et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001; 12: 47-51. (Pubitemid 32162447)
8. Burris HA, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413. (Pubitemid 27251144)
9. Glimelius B, Hoffman K, Sjoeden PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600. (Pubitemid 26285639)
10. Yamamoto T, Tanigawa N. The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc 2001; 34: 207-212.
11. Karin M, Greten FR. NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-759. (Pubitemid 41400849)
12. El-Hashash AHK, Esbrit P, Kimber SJ. PTHrP promotes murine secondary trophoblast giant cell differentiation through induction of endocycle, upregulation of giant - cell - promoting transcription factors and suppression of other trophoblast cell types. Differentiation 2005; 73: 154-174. (Pubitemid 41632504)
13. LaPensee CR, Hugo ER, Ben-Jonathan N. Insulin stimulates interleukin-6 expression and release in LS14 human adipocytes through multiple signaling pathways. Endocrinology 2008; 149: 5415-5422.
14. Findlay M, Von Minckwitz G, Wardley A. Effective oral chemotherapy for breast cancer: pillars of strength. Ann Oncol 2008; 19: 212-222. (Pubitemid 351201700)
15. Kim C, Lee JL, Ryu MH et al. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Investig New Drugs 2011; 29: 366-373.
16. Tiersten AD, Nelsen C, Talbotet S al. A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma. Cancer 2003; 97: 537-544. (Pubitemid 36125830)
17. Yang PC. National Research Program for Genomic Medicine Mechanisms of Metastasis and Progression of Lung Cancer. Journal Compilation. Blackwell Publishing Asia Pty Ltd Asia-Pac. J Clin Oncol 2006; 2: A1-A25.
18. Akasaka K, Maesawa C, Shibazaki M et al. Loss of class III β-tubulin induced by histone deacetylation is associated with chemosensitivity to paclitaxel in malignant melanoma cells. J Investig Dermatol 2009; 129: 1516-1526.
19. Garcea G, Neal C, Pattenden C, Steward W, Berry D. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer 2005; 41: 2213-2236. (Pubitemid 41415597)
20. Clark JCM, Dass CR, Choong PFM. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 2008; 134: 281-297. (Pubitemid 351170066)
21. Balcer-Kubiczek EK, Garofalo MC. Molecular Targets in Gastric Cancer and Apoptosis. Apoptosis Carcinogen Chemother 2009; 74: 824-830.
22. Zhou S, Qu X, Yu Z et al. Survivin as a potential early marker in the carcinogenesis of oral submucous fibrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol 2010; 109: 575-581.
23. Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM, Ryan BM. Survivin: a promising tumor biomarker. Cancer Lett 2007; 249: 49-60. (Pubitemid 46442669)
24. Acevedo-Duncan M, Win HY, Salup R. Prostate carcinogenesis predictor. In US Patent App. 20,090/130,195,2008.
25. Liu B, Staren E, Iwamura T, Appert H, Howard J. Taxotere resistance in pancreatic carcinoma cell line SUIT 2 and its sublines. World J Gastroenterol 2001; 7: 855-859. (Pubitemid 34051507)
26. Lambert L, Keyomarsi K. Cell Cycle Deregulation in Breast Cancer: Insurmountable Chemoresistance or Achilles' Heel? Breast Cancer Chemosensitivity 2007; 608: 52-69.
27. Porrata LF, Adjei AA. The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours. Br J Cancer 2001; 85: 484-489. (Pubitemid 32808268)
28. Xiao ZF, Yang ZY, Liang J et al. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann Thor Surg 2003; 75: 331-336. (Pubitemid 36184465)
29. Jadvar H, Tatlidil R, Garcia A, Conti P. Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. Clin Radiol 2003; 58: 215-221. (Pubitemid 36335946)
30. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004; 4: 448-456. (Pubitemid 38745530)
31. Schmidt M, Bastians H. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist Updates 2007; 10: 162-181. (Pubitemid 47449762)
32. Trivedi M, Budihardjo I, Loureiro K, Reid TR, Ma JD. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer. Future Oncol 2008; 4: 483-500.
33. McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 2008; 1785: 96-132.
34. Di Michele M, Della Corte A, Cicchillitti L et al. A proteomic approach to paclitaxel chemoresistance in ovarian cancer cell lines. Biochim Biophys Acta 2009; 1794: 225-236.
35. Schettino C, Bareschino MA, Maione P, Rossi A, Ciardiello F, Gridelli C. The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer. Curr Genomics 2008; 9: 252-262. (Pubitemid 351864251)